SenderraRx Earns ACHC Reaccreditation in Specialty Pharmacy and Oncology Distinction
SenderraRx Earns ACHC Reaccreditation in Specialty Pharmacy and Oncology Distinction
PR Newswire
DALLAS, Oct. 15, 2026
DALLAS, Oct. 15, 2026 /PRNewswire/ -- SenderraRx announced that it has earned reaccreditation in Specialty Pharmacy from the Accreditation Commission for Health Care (ACHC), including a Distinction in Oncology. Reaccreditation reflects an independent evaluation against nationally recognized standards for specialty pharmacy quality, safety, and patient care. The Oncology Distinction recognizes Senderra's oncology-focused clinical oversight, medication management, patient education, adherence support, and care coordination for patients navigating complex cancer therapies.
"This recognition reflects the expertise and commitment our team brings to patients navigating complex cancer therapies," said Will Howard, CEO of Senderra Specialty Pharmacy. "Our role extends beyond dispensing medication. We help patients understand their treatment, coordinate with their care teams, and overcome challenges that could interrupt therapy. Earning the Oncology Distinction affirms the disciplined, patient-centered approach our team applies every day."
The ACHC reaccreditation adds to Senderra's existing URAC accreditations in Specialty Pharmacy and Mail Service Pharmacy under URAC's version 6.0 standards. Collectively, these accreditations demonstrate that Senderra's pharmacy operations, medication distribution, patient management, and service practices have been independently evaluated against current industry standards.
Accreditation is recognized by health plans, pharmacy benefit managers, and pharmaceutical manufacturers as an indicator of quality and may be considered in specialty pharmacy network and limited-distribution program participation. Maintaining accreditation from both ACHC and URAC supports Senderra's work with payer and manufacturer partners and its delivery of coordinated clinical and patient support services.
About SenderraRx
SenderraRx is the largest, national, independent specialty pharmacy that provides medications, clinical management, medication access support, and patient services for people with complex and chronic conditions. Senderra utilizes technology solutions to enhance the patient and provider experience while promoting greater access to care. We work together with patients, prescribers, pharmaceutical manufacturers, and payer partners to coordinate therapy, assure access and support continuity of care. For more information, visit www.senderrarx.com.
About ACHC
The Accreditation Commission for Health Care (ACHC) is a nonprofit accreditation organization founded in 1986 that offers nationally recognized accreditation programs for pharmacies and other healthcare providers. ACHC's Specialty Pharmacy Accreditation evaluates an organization's policies, processes, and patient outcomes against industry standards, and its distinctions recognize advanced expertise in specific areas of care, such as oncology. For more information, visit www.achc.org.
About URAC
Founded in 1990 as a non-profit organization, URAC is the independent leader in promoting health care quality and patient safety through renowned accreditation programs. URAC develops its evidence-based standards in collaboration with a wide array of stakeholders and industry experts. The company's portfolio of accreditation and certification programs spans the health care industry, addressing health equity, workplace mental health, health care management and operations, pharmacies, telehealth, health plans, medical practices and more. URAC accreditation is a symbol of excellence for organizations to showcase their validated commitment to quality and accountability. For more information, visit www.urac.org.
SOURCE Senderra Specialty Pharmacy
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
United States